Vancouver, British Columbia – March 21, 2016 – Qu Biologics Inc., an immunotherapy company developing Site Specific Immunomodulators (SSIs) for cancer and other inflammatory diseases, announced initial results from the QBECO-01 study, a 68-patient randomized, placebo-controlled clinical study for the treatment of moderate-to-severe Crohn’s disease.
Based on the Week 8 and preliminary Week 16 results, QBECO SSI appears safe and well-tolerated and demonstrates consistently positive trends throughout the treatment period of the trial, successfully establishing proof-of-concept in Crohn’s disease and supporting continued development of QBECO SSI in inflammatory bowel disease.
Dr. Hal Gunn, CEO of Qu Biologics stated, “The positive trends observed across patient groups at Week 8 and Week 16 support the further assessment of SSIs as a therapeutic alternative to current treatments which suppress immune function.”
Jim Pankovich, Qu Biologics’ VP, Clinical Operations and Drug Development, added, “We are encouraged with the results of the trial, which will help to optimize the design and implementation of subsequent inflammatory bowel disease trials. Full results from the QBECO-01 study, including an assessment of the potential for sustained remission 8 weeks after completion of SSI treatment, are expected in the fall.”
Qu Biologics’ QBECO-01 study is a randomized, placebo-controlled, double-blinded clinical trial involving 68 participants with moderate-to-severe Crohn’s disease. Participants were randomized (1:1) to treatment with QBECO SSI or placebo. The objectives of the study are to evaluate the safety and effectiveness of QBECO SSI for the treatment of Crohn’s disease. The clinical study is taking place at four Canadian sites, in Vancouver, Edmonton, Calgary and Toronto.
About QBECO SSI
Qu Biologics’ QBECO SSI is an investigational treatment derived from components of inactivated E. coli bacteria and is designed to restore the body’s innate immune response in the gastrointestinal tract, reversing the chronic inflammation underlying inflammatory bowel disease. QBECO SSI is currently being studied as a treatment for Crohn’s disease and ulcerative colitis. More information can be found at www.quibd.com.
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that are designed to stimulate an innate immune response in targeted organs, restoring normal immune function and reversing the chronic inflammation underlying many conditions including cancer and immune-related disease. The company is conducting clinical trials in Crohn’s disease, ulcerative colitis and recurrent lung cancer.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.quibd.com.
For more information regarding this press release, contact:
Qu Biologics Inc.
Phone: 604.734.1450 ext. 41491